Shareholder alert: investigation of provention bio announced by holzer & holzer, llc

Atlanta, georgia--(newsfile corp. - july 6, 2021) -  holzer & holzer, llc is investigating whether provention bio, inc. ("provention" or the "company") (nasdaq: prvb) complied with federal securities laws. on july 6, 2021, provention announced the issuance of a complete response letter ("crl") by the fda for the company's biologics license application ("bla") for the drug teplizumab. specifically, the fda noted that a recent study "failed to show pharmacokinetic comparability" and notified provention that...
PRVB Ratings Summary
PRVB Quant Ranking